HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Maintains $17 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has maintained a Buy rating on Travere Therapeutics (NASDAQ:TVTX) and kept the price target at $17.

March 13, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reaffirms a Buy rating on Travere Therapeutics with a $17 price target.
The reaffirmation of a Buy rating and a $17 price target by a reputable analyst firm like HC Wainwright & Co. typically signals a positive outlook on the stock, suggesting potential upside. This endorsement could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100